Chronic Kidney Disease Market
Report ID: SQMIG35D2374
Report ID: SQMIG35D2374
sales@skyquestt.com
USA +1 351-333-4748
Report ID:
SQMIG35D2374 |
Region:
Global |
Published Date: January, 2026
Pages:
194
|Tables:
92
|Figures:
71
Global Chronic Kidney Disease Market size was valued at USD 13.7 billion in 2024 and is poised to grow from USD 16.45 billion in 2025 to USD 71.22 billion by 2033, growing at a CAGR of 20.1% during the forecast period (2026-2033).
The global chronic kidney disease market growth is driven by rising prevalence of diabetes and high blood pressure, which are the two main causes of chronic kidney disease, are becoming more common around the world. The fact that the world's population is getting older makes things worse because kidney function naturally gets worse with age. Patients and healthcare providers are becoming more informed regarding CKD and seeking treatment can result in earlier identification and diagnosis of the disease. This will keep the demand for therapeutic drugs, intervention strategies, and technological treatments high.
There are problems with the global chronic kidney disease market analysis, even though things are looking good. The most difficult restriction is the cost of treatment, especially keeping track of the costs of dialysis and kidney transplants. The total costs are very high for patients, providers, and healthcare systems. Also, a lot of people with chronic kidney disease (especially those in the early stages of the disease) are likely to not be diagnosed. This makes it harder for therapeutic interventions to find a market in the early-stage population. In addition, kidney disease is long-lasting and often occurs with other health problems, which makes it harder to treat and develop new drugs.
How Are Novel Therapies and AI-Powered Diagnostics Transforming the Chronic Kidney Disease Market?
New treatments and improvements in the use of artificial intelligence (AI) in diagnostics are changing the global chronic kidney disease market trends. It's clear that new types of drugs, such as SGLT2 inhibitors and non-steroidal MRAs, are very good at slowing the progression of chronic kidney disease. These drugs are a big step forward in treatment that goes beyond just controlling blood pressure. At the same time, new AI algorithms are being created to analyse patient data from electronic health records so that they can better predict the risk of CKD progression and allow for earlier and more targeted interventions.
In late 2024, a well-known example of real-world data was published for AstraZeneca's drug Farxiga (an SGLT2 inhibitor). It showed that the drug lowers the risk of kidney failure and heart problems in a wide range of patients with chronic kidney disease. These pieces of information all point to a new standard of care that is changing.
Market snapshot - 2026-2033
Global Market Size
USD 13.5 Billion
Largest Segment
Dialysis
Fastest Growth
Pharmaceuticals
Growth Rate
19.6% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global Chronic Kidney Disease Market is segmented by Product type, End Users and region. Based on Product type, the market is segmented into Diagnostic Type and Treatment Type. Based on End Users, the market is segmented into Hospitals, Dialysis Centers, Diagnostic Laboratories, Homecare, Specialty Clinics and Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
The Dialysis segment has the biggest share of the global chronic kidney disease market. This is mostly because it costs a lot of money to care for dialysis patients with end-stage renal disease (ESRD) repeatedly. Even though hours of service are spent on a much smaller group of patients than in earlier stages of chronic kidney disease, the intensity of hemodialysis and peritoneal dialysis, as well as the equipment, consumables, and clinical service component, create huge and ongoing revenue.
The Pharmaceuticals segment of the global chronic kidney disease market outlook is growing the fastest because new types of drugs, like SGLT2 inhibitors and non-steroidal MRAs, are being developed. These new drugs work to slow the progression of the disease, and they have opened a huge and growing market for treating people with early stages of chronic kidney disease.
Stage 5 (End-Stage Renal Disease - ESRD) has the biggest effect on the size of the global chronic kidney disease market. This is because patients at this stage need expensive and life-saving treatments like dialysis or transplantation. Taking care of an ESRD patient for a year costs a lot more than taking care of a patient in the earlier stages of chronic kidney disease. This makes Stage 5 the biggest segment overall in terms of total market value.
The Stage 3 consumer segment is the fastest-growing part of the global chronic kidney disease market industry. This is because more people are being diagnosed and treated at this important middle stage of chronic kidney disease thanks to better diagnosis and new drugs that can slow the disease's progress. As more people learn about this stage and more patients are diagnosed and treated, the need for therapeutic interventions will keep going up.
To get detailed segments analysis, Request a Free Sample Report
North America is the most important region in the global chronic kidney disease regional outlook. A lot of people have diabetes and high blood pressure. North America has a strong healthcare system, patients can get an education, and many insurance plans cover the costs of expensive treatments like dialysis and new drugs. The market will stay focused on North America because of the major pharmaceutical companies and the same amount of focus on research and translational development.
The United States is dominating country in North America that sells chronic kidney disease. There are many reasons for this, but the most important ones are the high rates of chronic kidney disease and its risk factors, as well as the high cost of their healthcare system. A report from early 2025 in North America showed that the number of SGLT2 "standard of care" prescriptions had gone up a lot compared to past levels or standards. Recent updates to the recommendations from major medical associations have put SGLT2 inhibitors in the category of standard care for chronic kidney disease.
Canada has the fastest-growing chronic kidney disease market in North America. There are many reasons why the chronic kidney disease market in Canada is growing so quickly. One of them is that the population is getting older and the government is still focusing on managing chronic diseases. Canada's single-payer healthcare system makes it easier for people to get new, effective treatments quickly. Several recent and past developments have also included Canadian provinces making new chronic kidney disease medications available to the public. These changes will make it easier for patients to get chronic kidney disease treatments and help the market grow at the same time.
The global chronic kidney disease regional forecast says that the Asia Pacific Region will grow the fastest. Diabetes and high blood pressure are becoming more common in this area very quickly, and the population is also getting older and bigger. As healthcare in Asia Pacific grows, incomes rise, and more people become aware of and willing to seek treatment in countries like China and India, the number of people who get diagnosed with renal disease early and start treatment will continue to rise dramatically. The changing healthcare systems could lead to a huge market that hasn't been tapped yet, which is also a great chance for growth.
Japan has the largest share of the chronic kidney disease market in the Asia Pacific Region because it has an aging population and some of the highest rates of end stage renal disease (ESRD) in the world. Japan's universal healthcare system pays for all of dialysis. There have been some interesting news stories from Japan. Japanese scientists are working on regenerative medicine methods, one of which is a study that focuses on growing organoids of the kidney to see if they can be used as treatments in the future.
South Korea is growing quickly in the Asia Pacific chronic kidney disease market because of its advanced healthcare system and strong local pharmaceutical industry. One important factor in future growth is the continued focus on early detection. South Korea is starting a national health screening program as part of its recent efforts to deal with chronic kidney disease. This program's screening process clearly includes risk factors for chronic kidney disease. Because of this, chronic kidney disease can be found and treated sooner.
The global chronic kidney disease market revenue includes Europe, which is a developed and important market. This is because its healthcare systems are more advanced, its public healthcare policies are more comprehensive, and its population is older. Also, Europe relies heavily on evidence-based medicine, which is based on clinical evidence. This is why new clinically validated therapies for chronic disease are quickly adopted there. and big drug companies with strong research skills make this area a good place for our market opportunity.
Germany is the most important country in the European chronic kidney disease market. Germany has a lot of power over the chronic kidney disease market because it has the most people, the most healthcare spending, and easy access to healthcare. In addition, the German health authorities have recently announced their support for integrated care models between general practitioners and nephrologists to help manage chronic kidney disease patients. This is in addition to the country's large diagnostics industry.
The United Kingdom has the fastest-growing market for chronic kidney disease in Europe. This is because the National Health Service (NHS) is focused on getting better results for long-term conditions. Centralized data systems across NHS services have made this happen. For instance, the NHS is now using a lot of opt-in patient data to find groups of patients who are more likely to have worsening kidney problems. This lets them give proactive care to those patients who need it.
France is seeing a lot of growth in the European chronic kidney disease market because it has a good health care system and a lot of focus on supported and even home-based care, as well as paying for care at home. For instance, French companies and organizations have recently come up with new peritoneal dialysis systems that are easier to use so that more patients will choose to do their own care at home.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Rising Prevalence of Diabetes and Hypertension
Launch of Novel and Effective Therapies
High Cost of Treatment and Dialysis
Large Undiagnosed Patient Population
Request Free Customization of this report to help us to meet your business objectives.
The global chronic kidney disease industry trends show that the market is made up of big pharmaceutical companies and major dialysis service providers. In the pharmaceutical industry, companies like AstraZeneca, Boehringer Ingelheim, and Bayer control their markets with blockbuster drugs. Their plans include big clinical trials to follow up on other indications, aggressive marketing to doctors, and getting payers to pay for their product. Fresenius Medical Care and DaVita are the biggest companies in the dialysis field. They have big networks of clinics with all the equipment and services that go along with them.
The competitive landscape showed that it costs a lot of money to do research and development and that it takes a long time (years) to make a new drug. Biotechnology start-ups and tech companies are entering the chronic disease market with new therapeutic approaches to managing chronic diseases or digital solutions. They are putting a lot of effort into developing new therapies in areas like regenerative medicine, AI-powered diagnostic tools that can help predict how a disease will progress, and new devices for home dialysis or even a wearable artificial kidney. Their goal is to better slow the disease or make treatment less painful for patients.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global chronic kidney disease market is doing well because diabetes and high blood pressure, its main risk factors, are becoming more common. The trend is getting stronger and faster because the world's population is getting older. The introduction of new drugs that can slow the progression of the disease is changing the way it is diagnosed and evaluated, moving from advanced stages to earlier ones.North America is the fastest-growing region, which shows how quickly this growth is happening. The market is still going in the right direction, even though it costs a lot to treat people with later stages of chronic kidney disease and there are a lot of people who have chronic kidney disease but are not aware of it. The Dialysis market has the biggest share of the market, but it's a problem because it costs a lot of money repeatedly. The pharmaceutical industry is growing the fastest, which shows a shift toward early-stage, pre-emptive management.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 13.7 billion |
| Market size value in 2033 | USD 71.22 billion |
| Growth Rate | 20.1% |
| Base year | 2024 |
| Forecast period | 2026-2033 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Chronic Kidney Disease Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Chronic Kidney Disease Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Chronic Kidney Disease Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Chronic Kidney Disease Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Chronic Kidney Disease Market size was valued at USD 16.93 Billion in 2024 and is poised to grow from USD 20.34 Billion in 2025 to USD 88.03 Billion by 2033, growing at a CAGR of 20.1% during the forecast period (2026–2033).
The global chronic kidney disease industry trends show that the market is made up of big pharmaceutical companies and major dialysis service providers. In the pharmaceutical industry, companies like AstraZeneca, Boehringer Ingelheim, and Bayer control their markets with blockbuster drugs. Their plans include big clinical trials to follow up on other indications, aggressive marketing to doctors, and getting payers to pay for their product. Fresenius Medical Care and DaVita are the biggest companies in the dialysis field. They have big networks of clinics with all the equipment and services that go along with them. 'AstraZeneca (United Kingdom) ', 'Amgen Inc. (United States) ', 'Bayer AG (Germany) ', 'Fresenius Medical Care (Germany) ', 'DaVita Inc. (United States) ', 'F. Hoffmann-La Roche Ltd. (Switzerland) ', 'Baxter International Inc. (United States) ', 'Novartis AG (Switzerland) ', 'Johnson & Johnson (United States) ', 'Pfizer Inc. (United States) ', 'GlaxoSmithKline plc (GSK) (United Kingdom) ', 'AbbVie Inc. (United States) ', 'Boehringer Ingelheim International GmbH (Germany) ', 'Travere Therapeutics (United States) ', 'Vera Therapeutics (United States) ', 'ProKidney (United States) ', 'Akebia Therapeutics (United States) ', 'Calliditas Therapeutics AB (Sweden) ', 'Becton, Dickinson and Company (BD) (United States) ', 'Renalytix Plc (United Kingdom) '
The chronic kidney disease market is mostly made up of people with diabetes and high blood pressure, which are the two main causes of kidney damage. As these two major chronic diseases get worse, more people will need treatments, which will happen at the same time as more people get chronic kidney disease.
Shift Towards Early Diagnosis and Intervention: The global chronic kidney disease market outlook is changing. There is now more emphasis on early detection and management than on treating the disease when it is at its worst. There is a growing push to screen people who are at risk. The goal is to find new, effective drugs that can slow the disease's progress long before a person needs dialysis.
North America is the most important region in the global chronic kidney disease regional outlook. A lot of people have diabetes and high blood pressure. North America has a strong healthcare system, patients can get an education, and many insurance plans cover the costs of expensive treatments like dialysis and new drugs. The market will stay focused on North America because of the major pharmaceutical companies and the same amount of focus on research and translational development.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
